Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 adaptive randomized double-blind vehicle-controlled study of VVN1901 eye drops in moderate or severe neurotrophic keratitis
CTR20252086Phase 2Active
- Sponsor
- VivaVision Biotech
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VVN1901 in neurotrophic keratitis (NK), sponsored by VivaVision Biotech. Started May 2025; status: active.
02
Drugs
VVN1901
03
Conditions
neurotrophic keratitis (NK)
Beyond the preview
Go deeper on CTR20252086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252086.